A detailed history of Zacks Investment Management transactions in Arvinas, Inc. stock. As of the latest transaction made, Zacks Investment Management holds 89,827 shares of ARVN stock, worth $2.04 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
89,827
Previous 81,798 9.82%
Holding current value
$2.04 Million
Previous $2.18 Million 1.61%
% of portfolio
0.02%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.66 - $32.73 $189,966 - $262,789
8,029 Added 9.82%
89,827 $2.21 Million
Q2 2024

Aug 14, 2024

BUY
$24.46 - $40.4 $146,197 - $241,470
5,977 Added 7.88%
81,798 $2.18 Million
Q1 2024

May 15, 2024

BUY
$36.38 - $52.31 $150,103 - $215,831
4,126 Added 5.75%
75,821 $3.13 Million
Q4 2023

Feb 14, 2024

BUY
$14.19 - $42.33 $1.02 Million - $3.03 Million
71,695 New
71,695 $2.95 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.21B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Zacks Investment Management Portfolio

Follow Zacks Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zacks Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Zacks Investment Management with notifications on news.